Table 2 Baseline Patient Characteristics, Serum Steroid Hormone and VEGF levels
Group | Control (n = 111) | Breast Cancer (n = 89) | ||
|---|---|---|---|---|
Median age (IQR) yrs | 53 (41–61) | 57 (50–67) | ||
Menopausal Status (n) | Premenopausal (43) | Postmenopausal (68) | Premenopausal (25) | Postmenopausal (64) |
Median Oestrogen (IQR) pmol/l | 415.5(251.5–645.2) | <100 | 491.0(267.2–572.7) | <100 |
Median Progesterone (IQR) nmol/l | 2.5 (1.45–18.7) | 1.00 (0.8–1.1) | 4.7 (3.1–14.7) | 0.8 (0.67–1.47) |
Median sVEGF (IQR) pg/ml | 117.12 (73.36–295.58) | 306.67 (176.2–407.7)* | ||
|  | 143.3(56.4–240.4) | 177.8(91.9–312.9) | 225.1(98.2–344.4) | 326.0†(206.0–420.3) |
Median sVEGFp (IQR) pg/106 | 0.73 (0.34–1.24) | 1.08 (0.68–1.44)* | ||
|  | 0.58 (0.26–1.16) | 0.75(0.41–1.30) | 0.77 (0.31–1.4) | 1.11 †(0.80–1.47) |